Table 2.
Measures of simulated driving performance.
| Simulated drive 1 | Simulated drive 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Placebo | 15 mg | 300 mg | 1500 mg | Placebo | 15 mg | 300 mg | 1500 mg | |
| Car Following component | ||||||||
| SDLP (cm) | 20.0 ± 4.2 | 21.0 ± 5.4 | 21.4 ± 3.7 | 21.4 ± 4.3 | 21.7 ± 5.5 | 21.2 ± 5.1 | 21.0 ± 5.4 | 20.4 ± 5.5 |
| Headway (m) | 81.5 ± 66.2 | 102.5 ± 93.0 | 96.7 ± 103.2 | 89.7 ± 81.8 | 90.8 ± 73.4 | 102.6 ± 109.3 | 93.9 ± 73.2 | 93.0 ± 86.1 |
| SD Headway (m) | 18.3 ± 7.8 | 27.2 ± 21.2 | 22.5 ± 16.3 | 20.7 ± 12.6 | 26.9 ± 23.8 | 26.6 ± 20.3 | 25.4 ± 11.2 | 22.6 ± 11.0 |
| Standard componenta | ||||||||
| SDLP (cm) | 34.4 ± 5.1 | 32.8 ± 4.8 | 33.4 ± 6.2 | 33.5 ± 5.9 | 34.3 ± 4.9 | 33.9 ± 6.1 | 34.4 ± 4.0 | 33.7 ± 6.2 |
| Speed (km/h) | 100.1 ± 6.2 | 98.9 ± 6.4 | 99.0 ± 5.1 | 99.7 ± 5.4 | 103.2 ± 11.7 | 100.6 ± 5.4 | 101.1 ± 5.5 | 101.3 ± 7.0 |
| SD Speed (km/h) | 13.0 ± 2.4 | 14.1 ± 3.6 | 12.2 ± 2.0 | 12.9 ± 2.5 | 13.5 ± 3.1 | 12.8 ± 3.1 | 12.2 ± 2.4 | 12.5 ± 2.9 |
SD: standard deviation; SDLP: standard deviation of lateral position.
Values are Mean ± SD.
a
Sample size was n = 16 as one participant failed to complete the Standard Drive on each occasion (see section ‘Expectancies and adverse events’).
Drive 1 was completed ~45–75 min post-treatment and Drive 2 was completed ~180–210 min post-treatment. The measures obtained during the standard component of these simulated drives may not be directly comparable to those obtained during previous studies utilising the same task as artefacts (e.g. lane crossing events) were removed in a subtly different (though in both cases, systematic) way.